Price Disclosure Reductions for 2021 October Cycle
Page last updated: 27 August 2021
This summary only includes medicines taking a price disclosure reduction on 1 October 2021. The determined price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).
The outcomes below show percentage (%) price differences and ex‑manufacturer level prices. They do not include fees and mark-ups. Information about publication of prices including fees and mark-ups is set out below.
Flow-on Reductions for F2 Combination Items
Responsible persons with a brand of an F2 combination item should note that:
- if an F2 combination item is listed below, it has met the criteria for a direct reduction. However, this reduction may not take effect on 1 October 2021 if the price of a component ingredient is also reduced and flowing on this component price reduction results in a lower price; or
- if an F2 combination item did not receive a direct price disclosure reduction, it may still receive a price reduction as a result of the flow-on of the price of a component ingredient that is taking a price disclosure reduction.
Outcomes for flow-on price disclosure reductions to F2 combination items will be communicated to responsible persons with brands of affected drugs in July 2021.
Legal Determination & Next Steps
The weighted average disclosed prices for each brand, including brands with a determination but no reduction, can be found in the legal determination on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Those brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their April 2021 PBS approved ex‑manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable and set out in the table below). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 31 March 2021 will also take the reduction on 1 October 2021 under section 99ADHA of the Act.
An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes was by 28 June 2021.
Indicative prices for 1 October 2021 (including price to pharmacy, dispensed price for maximum quantity and price premiums) were published in July 2021.
Final prices for 1 October 2021 reductions (including all price to pharmacy, dispensed price for maximum quantity/amount and price premiums) will be available in September 2021.
Excel version of 2021 October Cycle Outcomes Summary
2021 October Cycle Outcomes Summary
|
2021 October cycle |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Legal Instrument Drug |
Legal Instrument MoA |
Legal Instrument Form |
Average AEMP ($) |
WAPD |
WADP - |
April '21 AEMP ($) |
Percentage difference between April '21 and October '21 PBS prices (AEMP) (%) per |
Calculations based on: |
Unadjusted Price Reduction threshold (%) |
|
|
|
|
[Average AEMP minus WAPD = WADP] |
[Difference between April '21 |
|
|
|||
|
abacavir with lamivudine |
Oral |
Tablet containing abacavir 600 mg (as hydrochloride) with lamivudine 300 mg |
249.03 |
56.55% |
108.20 |
249.03 |
56.55% |
GWAPD |
10 |
|
abacavir with lamivudine |
Oral |
Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg |
249.03 |
56.55% |
108.20 |
249.03 |
56.55% |
GWAPD |
10 |
|
acamprosate |
Oral |
Tablet (enteric coated) containing acamprosate calcium 333 mg |
95.53 |
11.41% |
84.63 |
95.53 |
11.41% |
Does not meet 30 month clock |
10 |
|
azacitidine |
Injection |
Powder for injection 100 mg |
156.61 |
38.61% |
96.14 |
156.61 |
38.61% |
GWAPD |
30 |
|
bosentan |
Oral |
Tablet 125 mg (as monohydrate) |
898.26 |
52.06% |
430.63 |
612.64 |
29.71% |
GWAPD |
10 |
|
bosentan |
Oral |
Tablet 62.5 mg (as monohydrate) |
898.26 |
52.06% |
430.63 |
612.64 |
29.71% |
GWAPD |
10 |
|
dutasteride |
Oral |
Capsule 500 micrograms |
15.50 |
10.58% |
13.86 |
15.50 |
10.58% |
GWAPD |
10 |
|
ezetimibe |
Oral |
Tablet 10 mg |
12.71 |
24.69% |
9.57 |
10.83 |
11.63% |
Does not meet 30 month clock |
10 |
|
fenofibrate |
Oral |
Tablet 145 mg |
15.27 |
22.83% |
11.78 |
15.27 |
22.86% |
Does not meet 30 month clock |
10 |
|
fenofibrate |
Oral |
Tablet 48 mg |
10.18 |
22.83% |
7.86 |
10.18 |
22.79% |
Does not meet 30 month clock |
10 |
|
ganciclovir |
Injection |
Powder for I.V. infusion 500 mg (as sodium) |
158.37 |
26.70% |
116.09 |
132.19 |
12.18% |
Does not meet 30 month clock |
10 |
|
hyoscine |
Injection |
Injection containing hyoscine butylbromide 20 mg in 1 mL |
10.03 |
12.37% |
8.79 |
10.03 |
12.36% |
GWAPD |
10 |
|
imatinib |
Oral |
Capsule 100 mg (as mesilate) |
416.18 |
30.24% |
290.33 |
416.18 |
30.24% |
GWAPD |
30 |
|
imatinib |
Oral |
Capsule 400 mg (as mesilate) |
832.35 |
30.24% |
580.65 |
832.35 |
30.24% |
GWAPD |
30 |
|
imatinib |
Oral |
Tablet 100 mg (as mesilate) |
416.18 |
30.24% |
290.33 |
416.18 |
30.24% |
GWAPD |
30 |
|
imatinib |
Oral |
Tablet 400 mg (as mesilate) |
832.35 |
30.24% |
580.65 |
832.35 |
30.24% |
GWAPD |
30 |
|
lincomycin |
Injection |
Injection 600 mg (as hydrochloride monohydrate) in 2 mL |
79.78 |
25.07% |
59.78 |
79.78 |
25.07% |
Does not meet 30 month clock |
10 |
|
pregabalin |
Oral |
Capsule 150 mg |
18.42 |
31.28% |
12.66 |
14.47 |
12.51% |
GWAPD |
10 |
|
pregabalin |
Oral |
Capsule 25 mg |
5.43 |
31.28% |
3.73 |
4.26 |
12.44% |
GWAPD |
10 |
|
pregabalin |
Oral |
Capsule 300 mg |
27.48 |
31.28% |
18.88 |
21.59 |
12.55% |
GWAPD |
10 |
|
pregabalin |
Oral |
Capsule 75 mg |
12.01 |
31.28% |
8.25 |
9.43 |
12.51% |
GWAPD |
10 |
|
rituximab* |
Injection |
Solution for I.V. infusion 100 mg in 10 mL |
388.87 |
44.41% |
216.17 |
310.53 |
30.39% |
Does not meet 30 month clock |
10 |
|
rituximab* |
Injection |
Solution for I.V. infusion 500 mg in 50 mL |
972.17 |
44.41% |
540.43 |
776.32 |
30.39% |
Does not meet 30 month clock |
10 |
|
sildenafil |
Oral |
Tablet 20 mg (as citrate) |
254.31 |
33.41% |
169.35 |
254.31 |
33.41% |
GWAPD |
30 |
|
teriflunomide |
Oral |
Tablet 14 mg |
511.19 |
14.96% |
434.72 |
511.19 |
14.96% |
Does not meet 30 month clock |
10 |
|
tobramycin |
Injection |
Injection 500 mg (as sulfate) in 5 mL (without preservative) |
247.11 |
33.56% |
164.18 |
247.11 |
33.56% |
GWAPD |
30 |
|
tobramycin |
Injection |
Injection 80 mg (as sulfate) in 2 mL (without preservative) |
20.27 |
33.56% |
13.47 |
20.27 |
33.55% |
GWAPD |
30 |
|
tobramycin |
Injection |
Injection 80 mg in 2 mL |
18.51 |
33.56% |
12.30 |
18.51 |
33.55% |
GWAPD |
30 |
|
trastuzumab* |
Injection |
Powder for I.V. infusion 150 mg |
470.25 |
32.96% |
315.26 |
375.39 |
16.02% |
Does not meet 30 month clock |
10 |
|
trastuzumab* |
Injection |
Powder for I.V. infusion 420 mg |
1316.69 |
32.96% |
882.71 |
1051.09 |
16.02% |
Does not meet 30 month clock |
10 |
|
trastuzumab* |
Injection |
Powder for I.V. infusion 60 mg |
188.10 |
32.96% |
126.10 |
150.16 |
16.02% |
Does not meet 30 month clock |
10 |
